AstraZeneca (ADR) (AZN)
Develops oncology-led medicines spanning rare diseases, cardiovascular care, metabolism, respiratory disease, and immunology.
$168.42
vs last close+0.32 (+0.19%)
Something off on this page? Send us feedback.
Next report
Oct 30, 26
in 38 days
EPS estimate
$2.62
Revenue estimate
$16.06B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Nov '25Feb '26Apr '26Jul '26Oct '26
Reported$2.10$2.48$2.18$2.38$2.12$2.58$2.63Pending
Estimate$2.07$2.20$2.18$2.28$2.09$2.57$2.50$2.62
Surprise+1.4%+12.7%0.0%+4.4%+1.4%+0.4%+5.2%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Nov '25Feb '26Apr '26Jul '26Oct '26
Reported$14.89B$13.59B$14.46B$15.19B$15.50B$15.29B$15.38BPending
Estimate$14.23B$13.81B$14.10B$14.78B$15.44B$14.93B$15.44B$16.06B
Surprise+4.7%−1.6%+2.5%+2.8%+0.4%+2.4%−0.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $2.65 | — | — |
| Sep 2027 | $2.97 | — | — |
| Jun 2027 | $2.74 | — | — |
| Mar 2027 | $2.83 | — | — |
| Dec 2026 | $2.46 | — | — |
| Oct 2026 | $2.62 | — | — |
| Jul 2026 | $2.50 | $2.63 | +5.2% |
| Apr 2026 | $2.57 | $2.58 | +0.4% |
| Feb 2026 | $2.09 | $2.12 | +1.4% |
| Nov 2025 | $2.28 | $2.38 | +4.4% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $2.65 | — | — | $17.62B | — | — | — |
| Sep 2027 | $2.97 | — | — | $16.98B | — | — | — |
| Jun 2027 | $2.74 | — | — | $16.30B | — | — | — |
| Mar 2027 | $2.83 | — | — | $16.11B | — | — | — |
| Dec 2026 | $2.46 | — | — | $16.70B | — | — | — |
| Oct 30, 2026 | $2.62 | — | — | $16.06B | — | — | — |
| Jul 27, 2026 | $2.50 | $2.63 | +5.2% | $15.44B | $15.38B | −0.3% | +0.2% |
| Apr 29, 2026 | $2.57 | $2.58 | +0.4% | $14.93B | $15.29B | +2.4% | −0.8% |
| Feb 10, 2026 | $2.09 | $2.12 | +1.4% | $15.44B | $15.50B | +0.4% | +2.7% |
| Nov 6, 2025 | $2.28 | $2.38 | +4.4% | $14.78B | $15.19B | +2.8% | +4.1% |
| Jul 29, 2025 | |||||||
| Apr 29, 2025 | |||||||
| Feb 6, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Jul 25, 2024 | |||||||
| Apr 25, 2024 | |||||||
| Feb 8, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Jul 28, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 9, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Jul 29, 2022 | |||||||
| Apr 29, 2022 | |||||||
| Feb 10, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 30, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 29, 2020 | |||||||
| Feb 14, 2020 | |||||||
| Oct 24, 2019 | |||||||
| Jul 25, 2019 | |||||||
| Apr 26, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Jul 26, 2018 | |||||||
| May 18, 2018 | |||||||
| Feb 2, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Jul 27, 2017 | |||||||
| Apr 27, 2017 | |||||||
| Feb 2, 2017 | |||||||
| Nov 10, 2016 | |||||||
| Jul 28, 2016 | |||||||
| Apr 29, 2016 | |||||||
| Feb 4, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Jul 30, 2015 |